Jean-Sébastien Claveau, M.D., M. Sc.

Santé Québec Est-de-l'Île-de-Montréal
Universitaire

Jean-Sébastien Claveau, M.D., M. Sc.

Hématologue, Professeur adjoint de clinique

L'équipe de l’IHOT

Médecin

Contact

Tél. : 514 252-3404

Dr Jean-Sébastien Claveau est un spécialiste en myélome multiple et en gammapathies monoclonales. Il possède également un intérêt pour la biostatistique et la spectrométrie de masse. Ses sujets de recherche portent sur l'épidémiologie et le pronostic des patients avec myélome multiple ou dyscrasie plasmocytaire.

Chercheur-boursier clinicien Junior 1 du FRQS : 2026-2030
Entrée en poste à l’Hôpital Maisonneuve-Rosemont : 2023

Formations

Fellowship en myélome multiple
Clinique Mayo, Rochester (États-Unis), 2021-2023
Maîtrise en sciences biomédicales
Université de Montréal (Canada), 2020-2022
Résidences en médecine interne et hématologie
Université de Montréal (Canada), 2015-2020
Doctorat en médecine
Université de Montréal (Canada), 2008-2011

Découvrez ses publications

30 septembre 2025
From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter Transformation

Mathias Castonguay , Marie-France Gagnon , Alexandre Le Nguyen, Rafik Terra, Sarah-Jeanne Pilon, Guylaine Lépine , Richard LeBlanc , Jean Roy , Sandra Cohen , Isabelle Fleury , Luigina Mollica , Olivier Veilleux , Jean-Sébastien Claveau

DOI 10.3390/curroncol32100550 PMID 41149470

Consulter
9 juin 2025
Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma

Jean-Sébastien Claveau , Prashant Kapoor, Moritz Binder, Francis K Buadi, David Dingli, Angela Dispenzieri, Amie L Fonder, Morie A Gertz, Wilson I Gonsalves, Suzanne R Hayman , Miriam A Hobbs, Lisa Hwa Christenson, Taxiarchis V Kourelis, Martha Q Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A Kyle, S Vincent Rajkumar, Shaji K Kumar

DOI 10.1182/blood.2024027949 PMID 40489635

Consulter
20 mai 2025
Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Mathias Castonguay , Jean Roy , Jean-Sébastien Claveau , Sylvie Lachance , Jean-Sébastien Delisle , Thomas Kiss , Sandra Cohen , Isabelle Fleury , Luigina Mollica , Imran Ahmad , Nadia Bambace , Léa Bernard , Denis-Claude Roy , Guy Sauvageau , Olivier Veilleux

DOI 10.3390/curroncol32050285 PMID 40422544

Consulter
17 mai 2025
Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients

Rafik Terra, Stéphanie Thiant , Jean-Sébastien Claveau , Jean Roy , Imran Ahmad , Richard LeBlanc

DOI 10.1038/s41409-025-02626-x PMID 40379906

Consulter
18 avril 2025
Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Andrée-Anne Pelland, Mathilde Dumas, Émilie Lemieux-Blanchard , Richard LeBlanc , Julie Côté, Jean-Samuel Boudreault, Dominic Duquette, Rayan Kaedbey, Marc Lalancette, Frédéric Larose, Anna Nikonova, Michel Pavic, April Shamy , Jean Roy , Michael Sebag, Sabrina Trudel , Jean-Sébastien Claveau

DOI 10.3390/curroncol32040238 PMID 40277794

Consulter
8 avril 2025
Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes

Charalampos Charalampous , Jean-Sébastien Claveau , Prashant Kapoor, Moritz Binder, Francis K. Buadi, Joselle Cook, David Dingli, Angela Dispenzieri, Amie L. Fonder, Morie A. Gertz, Wilson Gonsalves, Suzanne R. Hayman, Miriam A. Hobbs, Yi L. Hwa, Taxiarchis Kourelis , Martha Q. Lacy, Nelson Leung, Yi Lin, Rahma Warsame, Robert A. Kyle, S. Vincent Rajkumar, Shaji K. Kumar

DOI 10.1182/bloodadvances.2024013355 PMID 39883947

Consulter
17 juin 2024
Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Jean-Sébastien Claveau , David L. Murray, Angela Dispenzieri, Prashant Kapoor, Moritz Binder, Francis Buadi, David Dingli, Amie Fonder, Morie Gertz, Wilson Gonsalves, Suzanne Hayman, Miriam Hobbs, Yi Lisa Hwa, Taxiarchis Kourelis, Martha Lacy, Nelson Leung, Yi Lin, Rahma Warsame , Robert A. Kyle, Vincent Rajkumar & Shaji K. Kumar

DOI 10.1038/s41375-024-02307-6 PMID 38886490

Consulter
22 septembre 2023
Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

Amélie Giguère, Isabelle Raymond-Bouchard, Vanessa Collin , Jean-Sébastien Claveau , Josée Hébert , Richard LeBlanc

DOI 10.3390/cancers15194687 PMID 37835381

Consulter
23 mai 2023
Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes

Mégane Tanguay, Christophe Dagenais , Richard LeBlanc , Imran Ahmad , Jean-Sébastien Claveau , Jean Roy

Consulter
29 janvier 2023
Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD

Jean-Sébastien Claveau , Richard LeBlanc , Imran Ahmad , Jean-Sébastien Delisle , Sandra Cohen , Thomas Kiss , Nadia Bambace , Léa Bernard , Sylvie Lachance , Denis-Claude Roy , Guy Sauvageau , Olivier Veilleux , Jean Roy

DOI 10.1016/j.jtct.2022.10.022 PMID 36334654

Consulter
28 mars 2022
Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

Olivier Veilleux , Jean-Sébastien Claveau , Habiba Alaoui , Jean Roy , Imran Ahmad , Jean-Sébastien Delisle , Thomas Kiss , Nadia M Bambace , Léa Bernard , Sandra Cohen , Guy Sauvageau , Isabelle Fleury , Luigina Mollica , Denis-Claude Roy , Yasmina Serroukh , Sylvie Lachance

DOI 10.1016/j.jtct.2021.12.005 PMID 34954149

Consulter
5 janvier 2022
Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

Jean-Sébastien Claveau , Sophie Savary Bélanger , Imran Ahmad , Jean-Sébastien Delisle , Vincent De Guire , Jean Roy , Richard LeBlanc

DOI 10.1038/s41408-021-00600-6 PMID 34987163

Consulter
10 décembre 2020
Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors

Jean-Sébastien Claveau , Sandra Cohen , Imran Ahmad , Jean-Sébastien Delisle , Thomas Kiss , Sylvie Lachance , Guy Sauvageau , Lambert Busque , Rose-Marie Brito, Nadia Bambace , Léa Bernard , Denis-Claude Roy , Jean Roy

DOI 10.1111/ejh.13504 PMID 32749758

Consulter
4 décembre 2020
Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only

Richard LeBlanc , Jean-Sébastien Claveau , Imran Ahmad , Jean-Sébastien Delisle , Nadia M Bambace , Léa Bernard , Sandra Cohen , Thomas Kiss , Sylvie Lachance , Séverine Landais , Denis-Claude Roy , Guy Sauvageau , Jean Roy

DOI 10.1111/ctr.14099 PMID 32981146

Consulter
5 octobre 2017
Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation

Jean-Sébastien Claveau , Richard LeBlanc , Imran Ahmad , J Ferreira, A-A Pistono, Nadia M Bambace , Léa Bernard , Sandra Cohen , Jean-Sébastien Delisle , Thomas Kiss , Sylvie Lachance , Jean Roy

DOI 10.1038/bmt.2017.154 PMID 28692025

Consulter

Jean-Sébastien Claveau, M.D., M. Sc.

Jean-Sébastien Claveau

Hématologue, Professeur adjoint de clinique

L'équipe de l’IHOT

Contact

Formations

Fellowship en myélome multiple

Maîtrise en sciences biomédicales

Résidences en médecine interne et hématologie

Doctorat en médecine

Découvrez ses publications

From Chronic Lymphocytic Leukemia to Plasmablastic Myeloma: Beyond the Usual Richter Transformation

Eliminating The Need for Sequential Confirmation of Response in Multiple Myeloma

Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center

Prognostic value and kinetic patterns of measurable residual disease following tandem autologous/allogeneic transplant in newly diagnosed myeloma patients

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma

Solitary plasmacytoma: single-institution experience, and systematic review and meta-analysis of clinical outcomes

Correction: Value of bone marrow examination in determining response to therapy in patients with multiple myeloma in the context of mass spectrometry-based M-protein assessment

Optical Genome Mapping Reveals the Complex Genetic Landscape of Myeloma

Young Myeloma Patients: A Systematic Review of Manifestations and Outcomes

Bortezomib Maintenance After Allogeneic Transplantation in Newly Diagnosed Myeloma Patients Results in Decreased Incidence and Severity of Chronic GVHD

Real-World Outcomes of Autologous and Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Hodgkin Lymphoma in the Era of Novel Therapies: A Canadian Perspective

Early free light chain reduction following treatment initiation predicts favorable outcome in intact immunoglobulin myeloma

Single UM171-expanded cord blood transplant can cure severe idiopathic aplastic anemia in absence of suitable donors

Newly diagnosed multiple myeloma patients treated with tandem auto-allogeneic stem cell transplant have better overall survival with similar outcomes at time of relapse compared to patients who received autologous transplant only

Cerebral adenovirus endotheliitis presenting as posterior reversible encephalopathy syndrome after allogeneic stem cell transplantation